B-intervention	0	11	Trastuzumab
O	12	15	for
O	16	24	patients
O	25	29	with
O	30	38	axillary
O	38	39	-
O	39	43	node
O	43	44	-
O	44	52	positive
O	53	59	breast
O	60	66	cancer
O	66	67	:
O	68	75	results
O	76	78	of
O	79	82	the
O	83	89	FNCLCC
O	89	90	-
O	90	94	PACS
O	95	97	04
O	98	103	trial
O	103	104	.

O	105	107	To
O	108	116	evaluate
O	117	120	the
O	121	129	efficacy
O	130	132	of
O	133	144	trastuzumab
O	145	147	in
O	148	156	patients
O	157	161	with
O	162	166	node
O	166	167	-
O	167	175	positive
O	176	182	breast
O	183	189	cancer
O	190	197	treated
O	198	202	with
O	203	210	surgery
O	210	211	,
O	212	220	adjuvant
O	221	233	chemotherapy
O	233	234	,
O	235	247	radiotherapy
O	247	248	,
O	249	252	and
O	253	260	hormone
O	261	268	therapy
O	269	271	if
O	272	282	applicable
O	282	283	.

O	284	289	Three
O	290	298	thousand
O	299	302	ten
O	303	311	patients
O	312	316	with
O	317	325	operable
O	326	330	node
O	330	331	-
O	331	339	positive
O	340	346	breast
O	347	353	cancer
O	354	358	were
O	359	367	randomly
O	368	376	assigned
O	377	379	to
O	380	387	receive
O	388	396	adjuvant
O	397	410	anthracycline
O	410	411	-
O	411	416	based
O	417	429	chemotherapy
O	430	434	with
O	435	437	or
O	438	445	without
O	446	455	docetaxel
O	455	456	.

B-eligibility	457	465	Patients
I-eligibility	466	469	who
I-eligibility	470	479	presented
I-eligibility	480	485	human
I-eligibility	486	495	epidermal
I-eligibility	496	502	growth
I-eligibility	503	509	factor
I-eligibility	510	518	receptor
I-eligibility	519	520	2
I-eligibility	521	522	(
I-eligibility	522	526	HER2
I-eligibility	526	527	)
I-eligibility	528	529	-
I-eligibility	529	543	overexpressing
I-eligibility	544	550	tumors
O	551	555	were
O	556	565	secondary
O	566	574	randomly
O	575	583	assigned
O	584	586	to
O	587	593	either
O	594	595	a
O	596	606	sequential
O	607	614	regimen
O	615	617	of
O	618	629	trastuzumab
O	630	631	(
O	631	632	6
O	633	635	mg
O	635	636	/
O	636	638	kg
O	639	644	every
O	645	646	3
O	647	652	weeks
O	652	653	)
O	654	657	for
O	658	659	1
O	660	664	year
O	665	667	or
B-control	668	679	observation
O	679	680	.

O	681	684	The
O	685	692	primary
O	693	696	end
O	697	702	point
O	703	706	was
B-outcome-Measure	707	714	disease
I-outcome-Measure	714	715	-
I-outcome-Measure	715	719	free
I-outcome-Measure	720	728	survival
I-outcome-Measure	729	730	(
I-outcome-Measure	730	733	DFS
I-outcome-Measure	733	734	)
O	734	735	.

O	736	743	Overall
B-total-participants	744	747	528
O	748	756	patients
O	757	761	were
O	762	770	randomly
O	771	779	assigned
O	780	787	between
O	788	799	trastuzumab
O	800	801	(
O	801	802	n
O	803	804	=
B-intervention-participants	805	808	260
O	808	809	)
O	810	813	and
O	814	825	observation
O	826	827	(
O	827	828	n
O	829	830	=
B-control-participants	831	834	268
O	834	835	)
O	836	839	arm
O	839	840	.

O	841	843	Of
O	844	847	the
O	848	851	234
O	852	860	patients
O	861	862	(
O	862	864	90
O	864	865	%
O	865	866	)
O	867	870	who
O	871	879	received
O	880	882	at
O	883	888	least
O	889	892	one
O	893	907	administration
O	908	910	of
O	911	922	trastuzumab
O	922	923	,
B-iv-bin-abs	924	927	196
O	928	929	(
B-iv-bin-percent	929	931	84
I-iv-bin-percent	931	932	%
O	932	933	)
B-outcome	934	942	received
I-outcome	943	945	at
I-outcome	946	951	least
I-outcome	952	953	6
I-outcome	954	960	months
I-outcome	961	963	of
I-outcome	964	973	treatment
O	973	974	,
O	975	978	and
B-iv-bin-abs	979	981	41
O	982	983	(
B-iv-bin-percent	983	985	18
I-iv-bin-percent	985	986	%
O	986	987	)
B-outcome	988	1000	discontinued
I-outcome	1001	1010	treatment
O	1011	1014	due
O	1015	1017	to
O	1018	1025	cardiac
O	1026	1032	events
O	1033	1034	(
O	1034	1037	any
O	1038	1043	grade
O	1043	1044	)
O	1044	1045	.

O	1046	1048	At
O	1049	1052	the
O	1053	1057	date
O	1058	1060	of
O	1061	1069	analysis
O	1070	1071	(
O	1071	1078	October
O	1079	1083	2007
O	1083	1084	)
O	1084	1085	,
O	1086	1089	129
B-outcome	1090	1093	DFS
I-outcome	1094	1100	events
O	1101	1105	were
O	1106	1114	recorded
O	1114	1115	.

O	1116	1122	Random
O	1123	1133	assignment
O	1134	1136	to
O	1137	1140	the
O	1141	1152	trastuzumab
O	1153	1156	arm
O	1157	1160	was
O	1161	1171	associated
O	1172	1176	with
O	1177	1178	a
O	1179	1193	nonsignificant
B-iv-bin-percent	1194	1196	14
I-iv-bin-percent	1196	1197	%
B-outcome	1198	1207	reduction
I-outcome	1208	1210	in
I-outcome	1211	1214	the
I-outcome	1215	1219	risk
I-outcome	1220	1222	of
I-outcome	1223	1230	relapse
O	1231	1232	(
O	1232	1238	hazard
O	1239	1244	ratio
O	1244	1245	,
O	1246	1247	0
O	1247	1248	.
O	1248	1250	86
O	1250	1251	;
O	1252	1254	95
O	1254	1255	%
O	1256	1258	CI
O	1258	1259	,
O	1260	1261	0
O	1261	1262	.
O	1262	1264	61
O	1265	1267	to
O	1268	1269	1
O	1269	1270	.
O	1270	1272	22
O	1272	1273	;
O	1274	1275	P
O	1276	1277	=
O	1278	1279	.
O	1279	1281	41
O	1281	1282	,
O	1283	1286	log
O	1286	1287	-
O	1287	1291	rank
O	1292	1302	stratified
O	1303	1305	on
O	1306	1316	pathologic
O	1317	1321	node
O	1322	1333	involvement
O	1333	1334	)
O	1334	1335	.

B-outcome	1336	1341	Three
I-outcome	1341	1342	-
I-outcome	1342	1346	year
I-outcome	1347	1350	DFS
O	1351	1356	rates
O	1357	1361	were
B-cv-bin-percent	1362	1364	78
I-cv-bin-percent	1364	1365	%
O	1366	1367	(
O	1367	1369	95
O	1369	1370	%
O	1371	1373	CI
O	1373	1374	,
O	1375	1377	72
O	1377	1378	.
O	1378	1379	3
O	1380	1382	to
O	1383	1385	82
O	1385	1386	.
O	1386	1387	5
O	1387	1388	)
O	1389	1392	and
B-iv-bin-percent	1393	1395	81
I-iv-bin-percent	1395	1396	%
O	1397	1398	(
O	1398	1400	95
O	1400	1401	%
O	1402	1404	CI
O	1404	1405	,
O	1406	1408	75
O	1408	1409	.
O	1409	1410	3
O	1411	1413	to
O	1414	1416	85
O	1416	1417	.
O	1417	1418	4
O	1418	1419	)
O	1420	1422	in
O	1423	1426	the
O	1427	1438	observation
O	1439	1442	and
O	1443	1454	trastuzumab
O	1455	1459	arms
O	1459	1460	,
O	1461	1473	respectively
O	1473	1474	.

O	1475	1480	After
O	1481	1482	a
O	1483	1485	47
O	1485	1486	-
O	1486	1491	month
O	1492	1498	median
O	1499	1505	follow
O	1505	1506	-
O	1506	1508	up
O	1508	1509	,
O	1510	1511	1
O	1512	1516	year
O	1517	1519	of
O	1520	1531	trastuzumab
O	1532	1537	given
O	1538	1550	sequentially
O	1551	1556	after
O	1557	1565	adjuvant
O	1566	1578	chemotherapy
O	1579	1582	was
O	1583	1586	not
O	1587	1597	associated
O	1598	1602	with
O	1603	1604	a
O	1605	1618	statistically
O	1619	1630	significant
O	1631	1639	decrease
O	1640	1642	in
O	1643	1646	the
O	1647	1651	risk
O	1652	1654	of
O	1655	1662	relapse
O	1662	1663	.
